



## NIH PUBLIC ACCESS

## Author Manuscript

APMIS. Author manuscript; available in PMC 2010 January 25.

Published in final edited form as:

APMIS. 2009 May ; 117(5-6): 458–476. doi:10.1111/j.1600-0463.2009.02453.x.

## Communication between *Toxoplasma gondii* and its host: impact on parasite growth, development, immune evasion, and virulence

IRA J. BLADER<sup>1</sup> and JEROEN P. SAEIJ<sup>2</sup><sup>1</sup>Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, BMSB 1034, 940 Stanton L. Young Blvd. Oklahoma City, OK 73104, USA. [iblader@ouhsc.edu](mailto:iblader@ouhsc.edu)<sup>2</sup>Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Building 68-270, Cambridge, MA 02139, USA. [jsaeij@mit.edu](mailto:jxaeij@mit.edu)

### Abstract

*Toxoplasma gondii* is an obligate intracellular protozoan parasite that can infect most warm-blooded animals and cause severe and life-threatening disease in developing fetuses and in immune-compromised patients. Although *Toxoplasma* was discovered over 100 years ago, we are only now beginning to appreciate the importance of the role that parasite modulation of its host has on parasite growth, bradyzoite development, immune evasion, and virulence. The goal of this review is to highlight these findings, to develop an integrated model for communication between *Toxoplasma* and its host, and to discuss new questions that arise out of these studies.

### Keywords

*Toxoplasma*; host–parasite interactions; apicomplexan; immune response

---

*Toxoplasma gondii* is an obligate intracellular protozoan parasite that can infect most warm-blooded animals. It is ubiquitous throughout the world and estimated to infect approximately half of the world's population. *Toxoplasma* is a member of the phylum Apicomplexa, which encompasses intracellular parasites characterized by a polarized cell structure and two unique apical secretory organelles named micronemes and rhoptries (1).

Studies on *Toxoplasma* are spurred on for two important reasons. First, *Toxoplasma* can cause severe and life-threatening disease (e.g. encephalitis, retinitis, and myocarditis) in developing fetuses and in immune-compromised patients. Although current available drugs can treat *Toxoplasma* infections, they are poorly tolerated, have severe side effects, and cannot act against chronic *Toxoplasma* infections. In addition, resistance to some of these drugs has recently been noted (2–4). Second, *Toxoplasma* is used as a model system for other disease-causing Apicomplexan parasites including *Plasmodium*, the causative agent of malaria; *Eimeria*, which is the cause of poultry coccidiosis; and *Cryptosporidium*, which is another important opportunistic infection in AIDS patients (5,6).

*Toxoplasma* has a complex life cycle consisting of a sexual cycle in its feline definitive hosts and an asexual cycle in its intermediate hosts (7). Intermediate hosts, including humans, can be infected by ingestion of oocysts shed in cat feces. Unlike most other Apicomplexan parasites, *Toxoplasma* can be transmitted between intermediate hosts by either vertical (mother–fetus) or horizontal (carnivorism) transmission.

*Toxoplasma* exists, in intermediate hosts, in two interconvertable stages: bradyzoites and tachyzoites. Bradyzoites are the slow-growing, transmissible, and encysted form that are dormant (8). Infections with bradyzoite-containing cysts occur upon ingestion of undercooked

meat. The wall of these cysts is digested inside of the host stomach and the released bradyzoites, which are resistant to gastric peptidases, will subsequently invade the small intestine. Within the small intestine they convert into tachyzoites, which is the rapidly growing, disease-causing form. Tachyzoites, which can infect most nucleated cells, replicate inside a parasitophorous vacuole (PV), egress, and then infect neighboring cells. These tachyzoites activate a potent host immune response that eliminates most of the parasites. Some tachyzoites, however, escape destruction and convert back into bradyzoites. In the absence of an adequate immune response, tachyzoites will grow unabated and cause tissue destruction, which can be severe and even fatal. However, the inflammatory immune response induced by tachyzoites can cause immune-mediated tissue destruction. Therefore, a subtle balance between inducing and evading the immune response is crucial for *Toxoplasma* to establish a chronic infection.

The success of *Toxoplasma* as a widespread pathogen is due to the ease in which it can be transmitted between intermediate hosts. Once inside a host the parasite has developed powerful tools to modulate its host cell and to develop into a chronic infection that can evade the host's immune system as well as all known anti-toxoplasmotic drugs. The ability of the parasite to replicate within a host cell, evade immune responses, and undergo bradyzoite development requires that the parasite effectively modulates its host. Recent work from several laboratories indicates that there are two major types of communication between *Toxoplasma* and its host. The first type is critical for parasite growth or bradyzoite development and does not appear to differ among distinct *Toxoplasma* strains. The second type of communication between *Toxoplasma* and its host differs among distinct *Toxoplasma* strains and likely results in strain-specific differences in pathogenesis. The goal of this review will be to highlight these findings, to develop an integrated model for communication between *Toxoplasma* and its host, and to discuss new questions that arise out of these studies.

## **TOXOPLASMA HIJACKS HOST ORGANELLES AND CYTOSKELETON**

*Toxoplasma* invasion is a complex process consisting of multiple, independently regulated steps. First, parasites attach loosely to the host cell's surface. This low affinity interaction is likely mediated by parasite surface proteins, most of which are GPI-linked proteins named SAGs (surface antigens), SRSs (SAG-related sequences), and SUSAs (SAG-unrelated surface antigens) (9,10). *Toxoplasma*'s unique ability to infect almost any nucleated cell and the large number of surface proteins expressed by tachyzoites suggests that loose attachment may be mediated by more than a single host molecule. Specific host receptors for any parasite surface protein have yet to be identified, although some SAGs appear to interact with sulfated glycosaminoglycans such as heparin (11–13).

Following attachment, an unknown signal triggers an increase in cytosolic calcium, which eventually stimulates microneme discharge. Although most of the players leading to microneme release are unknown, there is evidence that calcium-dependent protein kinases (CDPK) are involved; a *Toxoplasma* CDPK (TgCDPK1) that can regulate motility and invasion has been described (14) and purfalcamine, a compound that inhibits a *Plasmodium* CDPK, also inhibits *Toxoplasma* invasion (15). In addition to TgCDPK1, the *Toxoplasma* genome predicts the presence of several other CDPK that may also regulate microneme secretion and parasite invasion (16). At least 20 micronemal proteins have been identified and many of these are either transmembrane adhesins or accessory proteins for these adhesins (17).

Micronemal adhesin binding to host cells results in tight attachment between the parasite and the host cell (18). The parasite then uses a unique form of motility called gliding motility that is powered by the parasite's actomyosin machinery and is thought to be important for invasion (19,20). At some point, a second unknown trigger stimulates parasites to exocytose proteins from a second apical secretory organelle called the rhoptry. Four proteins, (RON2, RON4,

RON5, and RON8), localized to an elongated section of the rhoptries named the rhoptry neck, bind a micronemal protein named AMA1 after they are secreted (21,22). Together, these proteins form the moving junction, which is a complex on the host cell plasma membrane that migrates down the length of the parasite as invasion proceeds. It has been hypothesized that at least one component of the RON2, 4, 5, 8 complex traverses across the host plasma membrane and is exposed to the host cytoplasm (21).

As a parasite penetrates into its host cell it enters into the PV that forms concomitantly with invasion. Morphological and electro-physiological studies demonstrated that the lipids used to develop the PV are largely derived from the host plasma membrane and not from intracellular host organelles such as lysosomes, endoplasmic reticulum, and Golgi (23). *Toxoplasma* actively defines the protein composition of the PV by preventing the accumulation of most host transmembrane, but not GPI-linked, proteins (24,25). How this membrane partitioning is achieved is unknown as is its significance. It is, however, tempting to speculate that exclusion of host transmembrane proteins from the growing PV underlies the mechanism by which the parasite escapes the host endolysosomal system.

Although much progress has been made on defining the parasite machinery needed for invasion, little is understood about host cell structures involved in parasite invasion. Besides not knowing the host surface proteins that interact with micronemal adhesins or the moving junction complex, it is also not clear whether the parasite can invade any region of the plasma membrane or whether it searches for regions enriched in specific lipids and/or proteins.

Another outstanding question is whether the host plasma membrane, like the parasite's, needs to be anchored at the moving junction. The host actin cytoskeleton is one candidate to fill this role given its well-established role as a critical regulator of plasma membrane dynamics (26). In addition, two rhoptry proteins, Toxofilin and RON8, have been identified that interact with the host actin cytoskeleton and are exposed to the host cytoplasm during infection (21,27,28). But inhibitors of the actin cytoskeleton, which block parasite invasion, target parasite, but not host, actin (19). Thus, host actin may have a more subtle role during invasion and/or other host cytoskeletal elements like microtubules or intermediate filaments may also be important for invasion. If the host's cytoskeleton is important for invasion, how does the parasite act to regulate this structure? The most probable model involves a protein localized to the moving junction that interacts with the host cytoskeleton. Whether these are rhoptry proteins like Toxofilin and RON8 or a host protein is an unanswered but important question. A recent report showing that the host Arf6 GTPase localizes to the PV may provide some clues to these questions because this GTPase is an important regulator of membrane trafficking and the actin cytoskeleton (29,30).

## **TOXOPLASMA NUTRIENT ACQUISITION AND METABOLISM DURING INTRACELLULAR GROWTH**

All vacuolar pathogens face the challenge of scavenging nutrients from their host cells. Past biochemical studies coupled with bioinformatic analysis of the parasite's genome has identified a number of nutrients that *Toxoplasma* cannot synthesize *de novo* but must scavenge. These include small molecules such as glucose, arginine, iron, tryptophan, and purine nucleosides that can freely diffuse across the PV and then are presumably pumped into the parasite by membrane transporters (31–35). While most of these transporters have not yet been identified, a glucose transporter was cloned and characterized by heterologous expression in *Xenopus* oocytes (36).

But how *Toxoplasma* uses glucose as an energy source is, however, not clear. The parasite's genome indicates the presence of a full complement of glycolytic and Krebs' cycle enzymes.

In addition, *Toxoplasma* can efficiently perform oxidative phosphorylation (37). In contrast, pyruvate dehydrogenase, which converts pyruvate to acetyl-CoA is localized not to the mitochondrion but to another DNA-containing membrane-bound organelle, the apicoplast (38). Most significantly, parasite growth is only mildly affected in the absence of a functional Krebs's cycle. This is consistent with earlier findings showing that glucose is primarily broken down to lactic and acetic acids (39,40). Thus, it appears that *Toxoplasma* generates most of its ATP via substrate-level phosphorylation. But some of the prescribed anti-toxoplasmodic drugs (e.g. atovaquone) act by inhibiting the parasite's mitochondrial electron transport (37). Therefore, it is possible that the slight affect on parasite growth seen in the citric acid cycle mutant may still have a dramatic affect on *in vivo* growth and virulence.

In contrast to glucose and other small nutrients that passively diffuse across the PV and then are pumped into the parasite, other nutrients are obtained by more active, parasite-driven mechanisms. For example, *Toxoplasma* redirects LDL-mediated cholesterol transport to the PV by redirecting host microtubules and microtubule-based transport towards the PV (41). Electron micrographs show that host microtubules push into the PV and form elongated membranous tubules that contain LDL-loaded cholesterol. These membrane tubules are wrapped with a parasite-derived protein complex that includes the dense granule protein GRA7. This wrapping appears similar to dynamin and dynamin-like proteins that facilitate pinching off of vesicles from larger membranes. Recombinant GRA7 *in vitro* can stimulate liposome tubulation, suggesting that GRA7 may be involved in driving PV tubulation *in vivo* (41). But how the parasite internalizes cholesterol once it reaches the PV is still unknown. In addition to microtubules, host intermediate filaments are also reorganized around the PV but whether this is important in nutrient acquisition is not known (42).

Dr. David Roos and his colleagues have spearheaded an *in silico* effort to use *Toxoplasma* genomic sequence data (available at <http://toxodb.org/toxo/>) to develop metabolic pathway reconstruction maps (see [http://rooscompbio2.bio.upenn.edu/~fengchen/pathway\\_comparison\\_2/map01100.html](http://rooscompbio2.bio.upenn.edu/~fengchen/pathway_comparison_2/map01100.html)). These studies have helped define many of the nutrients that the parasite can synthesize *de novo*; however, the parasite still scavenges some of these nutrients from its host. For example, host-derived lipoic acid is metabolized by the parasite's mitochondrion even though lipoic acid is synthesized and used in the apicoplast (43). Why the parasite needs to scavenge lipoic acid from host cells is not clear but could be because of a lack of a lipoic acid transporter to export the nutrient out of the apicoplast.

How does the parasite ensure that it has access to host nutrients synthesized in host mitochondria and other organelles? One possible way is to relocalize host mitochondria and endoplasmic reticulum, which synthesize some of the nutrients the parasite needs, to the PV (44). Recruitment of these organelles occurs quickly after a parasite invades a cell. Antisense RNA-based assays indicated that the ROP2 rhopty protein acts to recruit mitochondria (45). ROP2 has an N-terminal domain that interacts with host mitochondria and a C-terminal portion that was originally proposed to span across the PV (45). This model has recently been challenged by the finding that proteins closely related to ROP2 are secreted into the host cytoplasm and interact with the PV as peripheral membrane proteins (46). Whether ROP2 and ROP2 family members (e.g. ROP3, ROP4, and ROP7) play similar functions in mediating organelle recruitment remains to be determined.

Another important, but less studied aspect of the interaction between *Toxoplasma* and its host is ensuring that the host has enough nutrients not only for the parasite but also for itself. Previous microarray studies surprisingly demonstrated an increase in host transcripts encoding glycolytic and mevalonate enzymes as well as the transferrin receptor (47,48). As discussed above, these genes encode proteins that function in pathways needed to help the parasite satisfy

its nutritional needs. It is, therefore, tempting to speculate that these changes in gene expression act to compensate for either differences in the metabolism or amounts of these nutrients within an infected cell.

The ability for the host to modulate nutrient pools is not only a property that the parasite may co-opt but also represents a critical mechanism for the host to restrict parasite growth. As an example, a key IFN $\gamma$  effector gene in humans is indoleamine dioxygenase that functions to catabolize tryptophan, which the parasite cannot synthesize *de novo* (32). Thus, tryptophan starvation is a critical anti-toxoplasmotic pathway in some but not all hosts.

## **TOXOPLASMA MODULATION OF HOST CELL CYCLE**

Regulating host cell cycle is a widely recognized mechanism for viruses to perfect their intracellular lifestyle (49). Evidence also indicates that this is not restricted to viruses and many microbial pathogens also manipulate their host's cell cycle. The most striking example among Apicomplexan parasites is *Theileria*, which transforms its host cells to facilitate its replication (50).

Two recent reports demonstrate that *Toxoplasma* is also able to dysregulate its host's cell cycle and causes host cells to arrest at the G2/M border (51,52). This effect on the host cell cycle was independent of the type of host cell and occurred in dividing and senescent cells (52). Importantly, RNAi-mediated knockdown of a gene involved in regulating the host cell cycle (UHRF1), which causes cells to arrest in G1, resulted in a significant reduction in parasite growth (51). Initial characterization of a factor that modulates the host cell cycle during infection indicated that it is a heat-labile factor larger than 10 kDa (53). Surprisingly, this factor was secreted from infected cells and could act on neighboring uninfected cells. Why would *Toxoplasma* want to affect the cell cycle of both infected and uninfected cells? One reason could be that the parasite is acting extrinsically on neighboring cells to prepare them for infection (53). Early studies supporting this hypothesis showed that *Toxoplasma* preferentially infects cells in the S-phase (54–56). Alternatively, host cell structures with which the parasite interacts (e.g. the MTOC) may not be accessible at other stages of the cell cycle (41,57).

## **TOXOPLASMA MODULATES HOST TRANSCRIPTION**

Changes in host gene expression are among the most common and widespread that takes place after infection. To understand the importance of these changes in *Toxoplasma*-infected cells, several groups have used DNA microarrays to examine changes in transcript abundance after infection (47,48,58). These experiments indicated that the expression levels of more than 1000 host genes were modulated. These genes encode proteins involved in many different processes including inflammation, apoptosis, metabolism, and cell growth and differentiation. The challenge to these types of studies is defining how each host gene contributes to the host-pathogen interaction. As a first step, the genes were clustered into three functionally distinct classes: (i) 'pro-host' – host genes required for host defense, (ii) 'pro-parasite' – host genes required for parasite growth, and (iii) 'bystander' – host genes incidentally regulated as a consequence of modulating the first two classes (47).

Potential pro-parasite genes upregulated by infection included those encoding glycolytic metabolic genes, transferrin receptor, and vascular endothelial growth factor. These candidate pro-parasite genes are regulated by a single host transcription factor named hypoxia-inducible factor 1 (HIF1) (59,60). HIF1, which is the key transcription factor in a cell's response to decreased oxygen levels, is a heterodimer consisting of  $\alpha$  and  $\beta$  subunits. *Toxoplasma* infection activates HIF1 and loss of the HIF1 $\alpha$  subunit leads to a significant reduction in parasite growth at physiological oxygen levels (61). The parasite factor that activates HIF1 is currently unknown but does not appear to be a byproduct of parasite oxygen consumption because other



hallmarks of hypoxic stress responses were not evident in *Toxoplasma*-infected cells (61). Rather HIF1 activation is mediated by a short-lived diffusible factor, which excludes a rhoptry-derived factor. This conclusion is also supported by the finding that upregulation of the transferrin receptor, which is another HIF1-target gene, is also mediated by a diffusible factor (48).

Besides HIF1, other host genes that encode transcription factors involved in cell growth and survival were also upregulated by infection. Among the earliest of these host genes were those encoding subunits of the EGR and AP-1 transcription factors (62,63). In contrast to HIF1, upregulation of one of these genes, EGR2, required direct contact between the host cell and parasite and appears to involve a rhoptry-derived factor. EGR and AP-1 transcription factors regulate genes involved in cell growth, survival, and differentiation. Given the well-documented roles that the EGR and AP-1 transcription factors play in stress responses (64–66), the activation of these stress response transcription factors may be important to help host cells survive the stress of the infection.

Nuclear factor- $\kappa$  B (NF- $\kappa$ B) is another transcription factor whose activity is modulated during infection (67–70). Although parasite modulation of NF- $\kappa$ B is debated in the *Toxoplasma* field, interest in this transcription factor was driven by two independent findings. First, loss of various NF- $\kappa$ B subunits leads to greater susceptibility during both acute and chronic infections (71–73). In addition, *Toxoplasma* prevents its host cell from undergoing apoptosis via NF- $\kappa$ B-dependent expression of pro-apoptotic genes (67,74) (for a more detailed discussion of *Toxoplasma* regulation of host cell apoptosis, we direct readers to an excellent recent review (75)).

The NF- $\kappa$ B family is composed of five members: p50 (NF- $\kappa$ B1), p52 (NF- $\kappa$ B2), p65 (RelA), RelB, and c-Rel (76). In unstimulated cells, homo- or hetero-dimers of NF- $\kappa$ B are sequestered in the cytoplasm by a family of inhibitors, called I $\kappa$ Bs (inhibitor of  $\kappa$  B). Activation of NF- $\kappa$ B is initiated by the degradation of I $\kappa$ B proteins. This occurs primarily via activation of kinases called I $\kappa$ B kinases (IKKs). When activated, IKK phosphorylates two serine residues in I $\kappa$ B, which leads to its ubiquitination and degradation by the proteasome. The NF- $\kappa$ B complex is then free to enter the nucleus where it can induce expression of specific genes that have NF- $\kappa$ B-binding sites in their promoter (77).

Activation of NF- $\kappa$ B by *Toxoplasma* is an area of controversy. Type I strains can transiently block NF- $\kappa$ B nuclear translocation in murine macrophages and human fibroblasts even though IKK activation and I $\kappa$ B degradation is not inhibited (70). This block in NF- $\kappa$ B translocation results in a decrease in the expression of inflammatory response genes such as IL-12p40 and TNF- $\alpha$  (70,78). In contrast, NF- $\kappa$ B is in the nuclei of *Toxoplasma*-infected murine fibroblasts and the transcription factor plays a role in the induction of anti-apoptotic genes (63,79). In infected murine fibroblasts, I $\kappa$ B $\alpha$  is phosphorylated but remarkably does not appear to be degraded (67). Instead, phosphorylated I $\kappa$ B $\alpha$  is found at the PVM where it may be phosphorylated by a parasite-encoded kinase (67,80). Differences between these studies might be due to different host cell types and/or host species being used but are most likely not due to differences in parasite strains because these studies all used a type I strain. In other work, however, differences in NF- $\kappa$ B activation have been associated with strain type: type II but not type I strains induce nuclear translocation of NF- $\kappa$ B in murine splenocytes (81) and bone marrow-derived macrophages (82). Furthermore, several microarray studies have demonstrated that cells infected with type II parasites have higher levels of NF- $\kappa$ B-regulated genes compared with uninfected cells (47,83).

## **TOXOPLASMA–HOST COMMUNICATION DURING BRADYZOITE DEVELOPMENT**

The ability of *Toxoplasma* to establish a chronic, asymptomatic infection by converting into transmissible tissue cysts that remain hidden from the host's immune system is an important feature of the parasite's life cycle that allows it to be such a successful and wide-spread pathogen (84). To establish a chronic infection, bradyzoites must form and the host must control tachyzoite proliferation. Bradyzoite development is a complex process that consists of changes in parasite gene and protein expression with the goal to slow its growth and escape detection by the host's immune system (85). Thus, there is a decrease in the expression of immunogenic surface proteins, metabolic enzymes, and an increase in the abundance of genes that act to facilitate entry into  $G_0$ .

*In vitro*, bradyzoite development can be triggered by factors that mimic immune-derived stressors such as high pH, IFN $\gamma$ , nitric oxide, high temperature, nutrient starvation, or by some drugs used to treat *Toxoplasma* infections (31,86–88). Thus, the parasite senses stress signals and uses these to develop into a persistent state that is relatively resistant to these stresses.

A role for the host cell in signaling tachyzoite to bradyzoite conversion was demonstrated by taking advantage of a drug, a trisubstituted pyrrole, designated Compound 1, which stimulated *in vitro* bradyzoite development (89). This drug acts by upregulating the abundance of the host gene CDA1, whose over expression leads to cell cycle arrest.

In primary muscle cells and neurons *Toxoplasma* spontaneously differentiates with high frequency into encysted bradyzoites, without the need for external stressors (90–92). Interestingly, neurons and muscle cells are terminally differentiated and permanently withdrawn from the cell cycle, which is in contrast to the typical cells most researchers use for *Toxoplasma* experiments (e.g. primary fibroblasts, macrophages, Vero cells, etc.). Together, these data suggest a model in which tachyzoite growth is favored inside of growing cells; but, when tachyzoites cannot manipulate the host's cell cycle (e.g. CDA1 upregulation or infection of terminally differentiated cells) bradyzoite development initiates. How the parasite senses replicating from non-replicating cells is not clear. One possibility is that infection of a terminally differentiated cells results in slower parasite growth, which is an important step in bradyzoite development (93,94).

Changes in parasite gene expression are an important facet of bradyzoite development and *Toxoplasma* surface proteins represent the largest group of stage-specific genes. For example, tachyzoites predominantly express SAG1, SAG2a, SAG3, SRS1, SRS2, and SRS3. In contrast, bradyzoites express a largely different repertoire of surface proteins including SAG2C, SAG2D, SAG2X, SAG2Y, SRS9, and SAG4. Many of these surface proteins are immunogenic and antibodies to them can be detected in sera from infected animals. SAG1 and SAG2 are considered the most immunogenic tachyzoite surface proteins and are believed to be critical in helping to limit tachyzoite proliferation (95–99). What the anti-*Toxoplasma* antibodies are doing is less clear because Fc $\gamma$ RII- or complement-deficient mice that receive sera from infected mice are protected just as well as wild-type mice (100), suggesting that complement-mediated lysis of parasites is not important. On the other hand, IgG purified from sera of infected animals reduce parasite invasion, suggesting that these antibodies act by preventing invasion, which is a critical step in the parasite's life cycle (95,100).

## **TOXOPLASMA ACTIVATION AND EVASION OF HOST IMMUNE RESPONSES**

Anti-*Toxoplasma* immune responses are generated at two distinct times – acute infections after a host is initially infected and reactivated infections after parasites are released from cysts.

Regardless of when or where the immune system encounters *Toxoplasma*, IL-12 release by dendritic cells, macrophages, and neutrophils is needed to stimulate IFN $\gamma$  secretion from both T-cells and NK cells (101,102).

IL-12 expression is triggered by *Toxoplasma* stimulating CCR5- and Toll-like receptor (TLR)-dependent signaling. CCR5 is a chemokine receptor expressed by multiple cell types including macrophages and dendritic cells (103). Mice lacking CCR5 express significantly lower amounts of IL-12 after *Toxoplasma* infection and CCR5<sup>+</sup> dendritic cells treated with *Toxoplasma* extracts upregulate IL-12 (104,105). Subsequent biochemical purification identified *Toxoplasma* cyclophilin-18 (C18) as a potential CCR5 ligand; but, the effect of C18 on CCR5-dependent IL-12 expression was relatively low, suggesting that other CCR5 ligands may be important for IL-12 expression.

TLRs are a family of at least 13 proteins that function to recognize pathogen-associated molecular patterns (106). TLR signaling is mediated by a series of adaptor proteins, the most prominent of which is MyD88. Several TLRs including TLR2, TLR4, and TLR11 bind *Toxoplasma*-derived factors (107–110). Unlike MyD88, which is essential for survival in parasite-infected animals, loss of individual TLRs has minimal impact on survival (107,111–113). These data indicate that either TLR signaling is functionally redundant or that MyD88 acts downstream of other receptors. These potential receptors include the IL-1 and IL-18 receptors both of which interact with MyD88 (114) and whose ligands are upregulated by infection (115–118).

Because MyD88 is important for host resistance, significant effort has been placed on identifying parasite-derived TLR ligands. Thus far, ligands for TLR11 (the actin-binding protein profilin) as well as TLR2 and TLR4 (HSP70 and GPI lipid anchors) have been described (107,108,110). In mice, profilin binding to TLR11 is most critical for stimulating IL-12 production (107,119). In addition, TLR11 is necessary for the development of CD4<sup>+</sup> T-cell responses to profilin (120). But it is not clear whether profilin is important in human disease because TLR11 is not functionally expressed in humans (121).

Although MyD88 is critical for primary responses to infection, it is less clear what role it plays in immunity to either reactivated or secondary infections. Mice lacking MyD88 specifically in their T-cells are susceptible to intraperitoneal parasite infections (122). In addition, loss of MyD88 blocks the ability for mice to develop Th1 responses when vaccinated with *Toxoplasma* lysates (123). In contrast, MyD88 is not essential to develop protective immune responses to oral infections in mice vaccinated with an attenuated parasite strain (124). The basis for these differences is most likely due to the infection route (oral vs intraperitoneal) and type of vaccination (lysate vs attenuated strain). Elucidating the mechanistic basis for these differences is, however, critical for vaccine and drug development.

IFN $\gamma$ , produced in response to parasite stimulation of IL-12 expression, is the critical cytokine for resistance to both acute and chronic *Toxoplasma* infections (125–127). Several IFN $\gamma$  effectors important for resistance have been identified including the IFN $\gamma$ -activated p47 family of GTPases (LRG47, IGTP, and IRG47), nitric oxide synthase, and indoleamine dioxygenase (32,128,129). These IFN $\gamma$  target genes affect parasite growth by different mechanisms. For example, the GTPases stimulate autophagy (130) and indoleamine dioxygenase sequesters tryptophan (32). With the exception of indoleamine dioxygenase, loss of most of these effectors in mice affects resistance to either acute or chronic infections, suggesting that they are expressed at either temporally or spatially distinct phases.

Although these data have helped define how various IFN $\gamma$  effectors protect against *Toxoplasma* in mice, some effectors are not present in humans; humans only have one p47 family member (131) and iNOS and nitric oxide, which are important for resistance in mice,



appear to have no significant role in protection in human cells (132,133). Thus, either the single human GTPase can function in place of the murine isoforms or other IFN $\gamma$  effectors are important in humans. One possible candidate is indoleamine dioxygenase, which is critical for resistance to *Toxoplasma* in human cells but does not appear to play any significant role in murine-derived cells (134–136).

IFN $\gamma$  regulates expression of its effector genes mainly through activation of the transcription factor STAT1 (137). When IFN $\gamma$  binds to its receptor it triggers the activation of Janus kinases (JAK1 and JAK2). These kinases phosphorylate STAT1 on tyrosine<sup>701</sup> residue, which subsequently leads to its dimerization, nuclear import, and binding to promoters of genes that contain consensus  $\gamma$ -activated sequence (GAS) sites. Some of the genes activated by STAT1 are other transcription factors such as interferon regulatory factor (IRF)-1 and the class II MHC transactivator (CTIIA). STAT1 alone or in combination with other transcription factors (such as IRF1) will induce the transcription of the effector genes important for resistance against *Toxoplasma*.

*Toxoplasma* has developed ways to subvert IFN $\gamma$  signaling thus allowing it to become a successful and widespread pathogen. Indeed, *Toxoplasma*-infected cells are significantly less responsive to IFN $\gamma$ -induced upregulation of many genes, including MHC Class II, iNOS, and the p47 GTPases (83,138). Because IFN $\gamma$  activation of the STAT1 signaling pathway is essential for the control of *Toxoplasma* growth, much effort has focused on how *Toxoplasma* inhibits the STAT1-mediated transcription in IFN $\gamma$ -stimulated cells. There is some evidence that *Toxoplasma* inhibits STAT1 by upregulating levels of suppressor of cytokine signaling (SOCS) proteins (139). SOCS are a family of eight proteins (SOCS1-7 and CIS) that are well-recognized attenuators of IFN $\gamma$ -dependent signaling (140). These proteins affect IFN $\gamma$  signaling by either inhibiting the catalytic activity of the JAKs (SOCS1, SOCS3) or by inhibiting recruitment of STATs (CIS). *Toxoplasma* infection of macrophages upregulates the abundance of SOCS-1, SOCS-3 and CIS mRNA levels. A role for these proteins in *Toxoplasma* immune evasion was established by demonstrating that when parasites infected macrophages stably overexpressing SOCS-1, SOCS-3, or CIS these macrophages could not produce nitric oxide or limit parasite growth in response to IFN $\gamma$  (139). Furthermore, *Toxoplasma* has a reduced ability to downregulate IFN $\gamma$  response genes (iNOS, MIG) in IFN $\gamma$ -activated macrophages from SOCS-1<sup>-/-</sup> mice. All these effects are dependent on viable parasite invasion and correlated with the number of invasion events consistent with the hypothesis that they are caused by a factor that *Toxoplasma* secretes into the host cell. These downregulatory effects on IFN $\gamma$  signaling were time-dependent and full inhibition was not achieved until 24 h post-infection, suggesting that *Toxoplasma* does not directly interfere with the initial IFN $\gamma$  response but rather acts by up-regulating SOCS proteins (139). Supporting such a mechanism was the observation that the levels of total STAT1 were reduced in *Toxoplasma*-infected macrophages, which is consistent with the ability of SOCS to target STAT1 for degradation (139). However, others have not observed any differences in total STAT1 levels in *Toxoplasma*-infected cells stimulated with IFN $\gamma$  (83,141). These studies suggested that *Toxoplasma* interferes with the binding of STAT1 to GAS elements leading to decreased expression of STAT1 responsive genes. The basis for these differences in the mechanism underlying parasite inhibition of IFN $\gamma$  is not clear, but could be because the work showing decreased STAT1 expression used high doses of type I parasites (139), while the other studies used lower doses of type II strains (83,141).

## **TOXOPLASMA DISSEMINATION IN THE HOST**

*Toxoplasma* disseminates rapidly from the initial site of infection to secondary lymphoid tissues and then on to other tissues (142,143). As the key cells that traffic from infected tissues to the spleen and draining lymph nodes, dendritic cells are likely candidates as the Trojan

Horse' that *Toxoplasma* uses to disseminate. In support of this hypothesis, early *in vitro* studies demonstrated that parasites preferentially infect and replicate inside of monocytes and dendritic cells (144). In addition, infection of dendritic cells increased their migratory capacity (145–147). Dendritic cell trafficking was pertussis toxin sensitive, suggesting that G<sub>i</sub>α-dependent chemokine receptors are important for trafficking (147). Most importantly, parasitized dendritic cells adoptively transferred to uninfected mice disseminated more quickly than uninfected cells (147). A more detailed phenotyping of these dendritic cells surprisingly revealed that they were not conventional dendritic cells but rather were a novel population of CD11c<sup>+</sup> cells that expressed both PDCA1 (a plasmacytoid dendritic cell marker) and CD11b (a myeloid cell marker) (148).

The above experiments used *in vitro* and intraperitoneal infection models to examine dendritic cell-based dissemination. But it is still not clear whether these dendritic cells are important for dissemination after an oral infection. A useful model to test this may be a transgenic mouse that expresses the diphtheria toxin receptor under control of the CD11c promoter. Injection of these mice with diphtheria toxin depletes almost all dendritic cells (149). Dissemination of GFP- or luciferase-expressing *Toxoplasma* could then be monitored in mock- or diphtheria toxin-treated mice. Unlike conventional plasmacytoid dendritic cells that are resistant to diphtheria toxin because they express low levels of CD11c (150), the PDCA1<sup>+</sup> cells in *Toxoplasma*-infected mice should be sensitive to the toxin because they expressed high levels of CD11c (151).

## IMPACT OF PARASITE GENOTYPE ON *TOXOPLASMA* HOST SIGNALING

*Toxoplasma* isolates from humans and livestock in Europe and North America group primarily into one of three clonal lineages (types I, II, and III) that can be discriminated in mice by their virulence (152–154). Type I strains are very virulent (LD<sub>100</sub> of one parasite). In contrast, types II and III strains are less virulent (LD<sub>50</sub> ~10<sup>3</sup> and ~10<sup>5</sup>, respectively (155)). In humans, all three lineages cause disease, but they appear to differ in the tissues they affect and when they infect people. For example, type I strains are more often associated with post-natally acquired ocular infections, whereas type II strains are more associated with congenital infections and toxoplasmic encephalitis (156).

Recently, it has become more appreciated that the various *Toxoplasma* strains differ profoundly in how they modulate host cell signaling pathways. For example, human foreskin fibroblasts (HFFs) infected with types I, II, or III strains have significantly different gene expression profiles (155). If the strain-specific regulation of a host gene has a genetic basis then it should segregate among F1 progeny derived from a cross between two strains that differ in regulation of that gene. Thus, human DNA microarrays were used to compare the transcriptional profile of HFFs infected with 19 unique F1 progeny derived from crosses between types II and III strains (157). These microarray experiments indicated that 3188 human cDNAs correlated with the allelic state of specific *Toxoplasma* genomic loci. Interestingly, the expression levels of 1176 of these cDNAs correlated with a single locus on *Toxoplasma* chromosome VIIIb. This suggested that in the vicinity of that locus there was at least one polymorphic *Toxoplasma* gene whose product had a major effect on HFF gene expression. Pathway analysis identified that many of the host genes regulated by this locus were targets of the STAT6 and STAT3 transcription factors (158), suggesting that many of the differences in modulation of host gene expression by the different *Toxoplasma* strains were due to differences in STAT3/6 signaling.

Data supporting this hypothesis included STAT3/6 activation for prolonged times in cells infected with types I and III strains (155). In contrast, STAT3/6 were only transiently activated in cells infected with type II strains. Subsequently, ROP16 was identified as the *Toxoplasma* protein mediating the strain-specific differences in maintaining STAT3/6 activation. While the

basis for the differences between the two ROP16 alleles is not yet known, it is not due to differences in the expression, host cell secretion, or nuclear localization of either allele.

No other polymorphic parasite factors that regulate host gene expression are currently known. However, the data suggest that at least one gene exists on each *Toxoplasma* chromosome that is involved in the strain-specific regulation of host gene expression (155). Given the precedent for rhoptry-localized kinases and kinase-like proteins (e.g. ROP16, ROP18, and ROP2, 3, 4) as key mediators in regulating *Toxoplasma* host interactions, it is possible that other secreted kinases may fill a similar role in regulating other host genes. Indeed, a search of the *Toxoplasma* genome database (<http://www.toxodb.org>) predicts that more than 70 predicted genes encode proteins that have signal peptides and have significant homology to protein kinases (Fig. 1).

## IMPACT OF PARASITE GENOTYPE ON *TOXOPLASMA*-INDUCED DISEASE

Virulence of type I strains is due in large part to over production of Th1 cytokines that cause tissue damage (116,159,160). In addition, type I parasites display enhanced migratory capacity across cellular barriers *in vitro* and *in vivo*, which may also contribute to virulence (161). Similarly, a virulent strain (named S23) derived from a cross between types II and III strains had a higher *in vivo* growth rate and disseminated more rapidly than an avirulent strain from the same cross (named S22) (162).

Recently, Taylor et al. (163) used QTL mapping of F1 progeny from a type I×III cross and identified a locus on chromosome VIIa that was tightly linked to virulence. The responsible gene was subsequently identified as ROP18. ROP18 is a rhoptry-localized, functional serine/threonine kinase that is secreted into host cells. Expression analysis indicated that ROP18 expression was significantly higher in type I than in type III strains. Importantly, transfer of the type I allele into the non-virulent type III strain increased virulence by more than four orders of magnitude. Virulence was dependent on the ROP18's kinase activity as transfer of a type I kinase dead mutant into a type III strain did not increase virulence. Although it is not clear how ROP18 functions, it is possible that its ability to increase parasite proliferation may enhance virulence (163,164). Likewise, ROP18 substrates have yet to be identified although recombinant ROP18 can phosphorylate an unknown 70-kDa parasite protein, but not proteins in host cell extracts (164).

In a separate study, Grigg et al. (165) found that two out of 16 progeny from a cross between avirulent types II and III strains were surprisingly more virulent than either parental strain or other progeny. These differences in virulence were not due to faster growth because there were no apparent differences in invasion or growth rates between the virulent and avirulent progeny (165). To identify the virulence genes, mice were infected with the types II and III parental strains and with 40 unique F1 progeny of a type II×III cross. QTL mapping from these experiments identified five *Toxoplasma* genomic regions associated with virulence (VIR1–5) (166).

Using a candidate gene approach, we identified VIR3 as ROP18, which was the same rhoptry kinase identified by Taylor et al. (166). Subsequent sequence analysis of the ROP18 gene (including promoter regions) from types I–III strains revealed that type III strains have a unique 2.1-kb sequence inserted 85 bp upstream of the ATG start codon. It seems likely that this insertion (relative to types I and II) in the 5'-untranslated region – promoter of the type III ROP18 allele is involved in the major difference in expression of this locus in type III strains (163,166).

Expressing the type II ROP18 allele in a type III strain increased virulence by four orders of magnitude (166), which is surprising because VIR3 was predicted to only account for ~10%

of the variance in virulence between type II and III strains. One possible explanation for ROP18's surprisingly high impact on virulence lies in the fact that in the transgenic type III: ROP18<sub>II</sub> strain, ROP18 was expressed about eight times higher than in the wild-type type II strain (166).

Using a similar candidate gene approach, VIR4 was identified as ROP16 on chromosome VIIb. Interestingly, expression of a type I or III allele of ROP16 in a type II strain made that strain less virulent. At the moment, it is unknown why the type II strain became less virulent but is likely due to ROP16's role in sustained STAT3/6 activation (155).

The genes responsible for the VIR1, VIR2 and VIR5 QTLs have yet to be identified. VIR1 has been mapped to a region spanning ~0.98 Mb on the left end of chromosome XII. Two interesting candidate genes are found within this region: (i) a surface antigen (SAG3), and (ii) a secreted rhoptry-localized putative protein kinase (ROP5). VIR2 falls within a ~1.2 Mb interval on chromosome X, and contains 139 predicted genes. Two candidate genes in this locus (genes 42.m03493 and 42.m03409 in the ToxoDB database) are both predicted to have signal peptides and at least one transmembrane domain but lack homology to other known proteins or domains. Finally, the VIR5 QTL is found in a region on chromosome XII where there are very few differences between types II and III strains. It should also be noted that this QTL is linked to resistance to adenosine arabinoside, which is due to a loss of function mutation in the adenosine kinase gene (167). It has been reported that a lack of functional adenosine kinase can result in fitness defects (168). Because the type III parent carries the adenosine arabinoside marker and this drug was used to select 23 of the 41 recombinant progeny, it is possible that adenosine kinase is the gene responsible for VIR5.

## CONCLUSIONS

Although *Toxoplasma* was discovered over 100 years ago (169,170), we are only now beginning to appreciate the importance of the role that parasite modulation of its host has on parasite growth, bradyzoite development, immune evasion, and virulence. These discoveries are significant not only because they taught us about *Toxoplasma*-specific processes but also because they illuminate novel biological processes. Recent examples include hijacking of microtubule-based LDL-trafficking, invasion via the RON complex, rhoptry injection of virulence factors, and IFN $\gamma$ -inducible GTPase-mediated autophagy. But many important questions remain about how *Toxoplasma* grows within its host. The development of new biochemical and genetic tools will facilitate studies to answer these questions. These tools include high-throughput RNAi and small molecule inhibitor screens that have already yielded important information about *Toxoplasma* invasion (171). In addition, the development of cosmid libraries to identify mutated genes in forward genetic screens will now allow many investigators to use chemical mutagenesis-based screens to identify parasite genes that modulate host cell functions (172).

Besides the topics we covered in this review, future *Toxoplasma* research will likely focus on understanding how epigenetic regulation of both parasite and host gene expression affect communication between *Toxoplasma* and its host. In addition, recent evidence has indicated that *Toxoplasma* infections can have significant effects on host behavior (173–176) and future work will likely aim to elucidate the molecular basis for these changes. Finally, the long-term goal of studying an important infectious disease like *Toxoplasma* is the development of protective vaccines as well as the production of effective drug therapies that have few side effects. Understanding the basic biology underlying the interaction between *Toxoplasma* and its host will greatly aid in reaching these goals.

## Acknowledgments

Our laboratories are funded by grants to I.J.B. from the National Institutes of Health (RO1AI069986) and the American Cancer Society (MBC-114461) and a Scientist Development Grant from the American Heart Association (0835099N) to J.P.S.

## REFERENCES

1. Dubey JP, Lindsay DS, Speer CA. Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. *Clin Microbiol Rev* 1998;11:267–99. [PubMed: 9564564]
2. Baatz H, Mirshahi A, Puchta J, Gumbel H, Hattenbach LO. Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient. *Ocul Immunol Inflamm* 2006;14:185–7. [PubMed: 16766403]
3. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, et al. The California Collaborative Treatment Group. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. *Ann Intern Med* 1992;116:33–43. [PubMed: 1727093]
4. Aspinall TV, Joynson DH, Guy E, Hyde JE, Sims PF. The molecular basis of sulfonamide resistance in *Toxoplasma gondii* and implications for the clinical management of toxoplasmosis. *J Infect Dis* 2002;185:1637–43. [PubMed: 12023770]
5. Dubey, JP. *Toxoplasma, Neospora, Sarcocystis*, and other tissue cyst-forming coccidia of humans and animals. In: Kreier, JP., editor. *Parasitic Protozoa*. Academic Press Inc.; San Diego, CA: 1993. p. 1-158.
6. Kim K, Weiss LM. *Toxoplasma gondii*: the model apicomplexan. *Int J Parasitol* 2004;34:423–32. [PubMed: 15003501]
7. Dubey JP. Toxoplasmosis – a waterborne zoonosis. *Vet Parasitol* 2004;126:57–72. [PubMed: 15567579]
8. Tenter AM, Heckeroth AR, Weiss LM. *Toxoplasma gondii*: from animals to humans. *Int J Parasitol* 2000;30:1217–58. [PubMed: 11113252]
9. Boothroyd JC, Hehl A, Knoll LJ, Manger ID. The surface of *Toxoplasma*: more and less. *Int J Parasitol* 1998;28:3–9. [PubMed: 9504330]
10. Pollard AM, Onatolu KN, Hiller L, Haldar K, Knoll LJ. Highly polymorphic family of glycosylphosphatidylinositol-anchored surface antigens with evidence of developmental regulation in *Toxoplasma gondii*. *Infect Immun* 2008;76:103–10. [PubMed: 17938221]
11. Ortega-Barria E, Boothroyd JC. A *Toxoplasma* lectin-like activity specific for sulfated polysaccharides is involved in host cell infection. *J Biol Chem* 1999;274:1267–76. [PubMed: 9880495]
12. Carruthers VB, Hakansson S, Giddings OK, Sibley LD. *Toxoplasma gondii* uses sulfated proteoglycans for substrate and host cell attachment. *Infect Immun* 2000;68:4005–11. [PubMed: 10858215]
13. He XL, Grigg ME, Boothroyd JC, Garcia KC. Structure of the immunodominant surface antigen from the *Toxoplasma gondii* SRS super-family. *Nat Struct Biol* 2002;9:606–11. [PubMed: 12091874]
14. Kieschnick H, Wakefield T, Narducci CA, Beckers C. *Toxoplasma gondii* attachment to host cells is regulated by a Calmodulin-like domain protein kinase. *J Biol Chem* 2001;276:12369–77. [PubMed: 11154702]
15. Kato N, Sakata T, Breton G, Le Roch KG, Nagle A, Andersen C, et al. Gene expression signatures and small-molecule compounds link a protein kinase to *Plasmodium falciparum* motility. *Nat Chem Biol* 2008;4:347–56. [PubMed: 18454143]
16. Nagamune K, Sibley LD. Comparative genomic and phylogenetic analyses of calcium ATPases and calcium-regulated proteins in the apicomplexa. *Mol Biol Evol* 2006;23:1613–27. [PubMed: 16751258]
17. Zhou XW, Kafsack BFC, Cole RN, Beckett P, Shen RF, Carruthers VB. The opportunistic pathogen *Toxoplasma gondii* deploys a diverse legion of invasion and survival proteins. *J Biol Chem* 2005;280:34233–44. [PubMed: 16002397]



18. Carruthers V, Boothroyd JC. Pulling together: an integrated model of *Toxoplasma* cell invasion. *Curr Opin Microbiol* 2007;10:83–9. [PubMed: 16837236]
19. Dobrowolski JM, Sibley LD. *Toxoplasma* invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. *Cell* 1996;84:933–9. [PubMed: 8601316]
20. Hakansson S, Morisaki H, Heuser J, Sibley LD. Time-lapse video microscopy of gliding motility in *Toxoplasma gondii* reveals a novel, biphasic mechanism of cell locomotion. *Molecular Biology of the Cell* 1999;3539–47. [PubMed: 10564254]
21. Straub K, Cheng S, Sohn C, Bradley P. Novel components of the Apicomplexan moving junction reveal conserved and coccidia-restricted elements. *Cell Microbiol* 2009;11:590–603. [PubMed: 19134112]
22. Alexander DL, Mital J, Ward GE, Bradley P, Boothroyd JC. Identification of the moving junction complex of *Toxoplasma gondii*: a collaboration between distinct secretory organelles. *PLoS Pathog* 2005;1:e17. [PubMed: 16244709]
23. Suss-Toby E, Zimmerberg J, Ward GE. *Toxoplasma* invasion: the parasitophorous vacuole is formed from host cell plasma membrane and pinches off via a fission pore. *Proc Natl Acad Sci USA* 1996;93:8413–8. [PubMed: 8710885]
24. Mordue DG, Desai N, Dustin M, Sibley LD. Invasion by *Toxoplasma gondii* establishes a moving junction that selectively excludes host cell plasma membrane proteins on the basis of their membrane anchoring. *J Exp Med* 1999;190:1783–92. [PubMed: 10601353]
25. Charron AJ, Sibley LD. Molecular partitioning during host cell penetration by *Toxoplasma gondii*. *Traffic* 2004;5:855–67. [PubMed: 15479451]
26. Sheetz MP, Sable JE, Dobreiner HG. Continuous membrane-cytoskeleton adhesion requires continuous accommodation to lipid and cytoskeleton dynamics. *Annu Rev Biophys Biomol Struct* 2006;35:417–34. [PubMed: 16689643]
27. Poupel O, Boleti H, Axisa S, Couture-Tosi E, Tardieux I. Toxofilin, a novel actin-binding protein from *Toxoplasma gondii*, sequesters actin monomers and caps actin filaments. *Mol Biol Cell* 2000;11:355–68. [PubMed: 10637313]
28. Bradley PJ, Ward C, Cheng SJ, Alexander DL, Collier S, Coombs GH, et al. Proteomic analysis of rhoptry organelles reveals many novel constituents for host–parasite interactions in *Toxoplasma gondii*. *J Biol Chem* 2005;280:34245–58. [PubMed: 16002398]
29. da Silva CV, da Silva EA, Cruz MC, Chavrier P, Isberg R, Mortara RA. ARF6, PI3-kinase and host cell actin cytoskeleton in *Toxoplasma gondii* cell invasion. *Biochem Biophys Res Commun* 2008;378:656–67. [PubMed: 19061866]
30. Gillingham AK, Munro S. The small G proteins of the Arf family and their regulators. *Annu Rev Cell Dev Biol* 2007;23:579–611. [PubMed: 17506703]
31. Fox BA, Gigley JP, Bzik DJ. *Toxoplasma gondii* lacks the enzymes required for de novo arginine biosynthesis and arginine starvation triggers cyst formation. *Int J Parasitol* 2004;34:323–31. [PubMed: 15003493]
32. Pfefferkorn ER. Interferon gamma blocks the growth of *Toxoplasma gondii* in human fibroblasts by inducing the host cells to degrade tryptophan. *Proc Natl Acad Sci USA* 1984;81:908–12. [PubMed: 6422465]
33. Perrotto J, Keister DB, Gelderman AH. Incorporation of precursors into toxoplasma DNA. *J Protozool* 1971;18:470–3. [PubMed: 5132320]
34. Schwartzman JD, Pfefferkorn ER. *Toxoplasma gondii*: purine synthesis and salvage in mutant host cells and parasites. *Exp Parasitol* 1982;53:77–86. [PubMed: 7198995]
35. Krug EC, Marr JJ, Berens RL. Purine metabolism in *Toxoplasma gondii*. *J Biol Chem* 1989;264:10601–7. [PubMed: 2732241]
36. Joet T, Holterman L, Stedman TT, Kocken CH, Van Der Wel A, Thomas AW, et al. Comparative characterization of hexose transporters of *Plasmodium knowlesi*, *Plasmodium yoelii* and *Toxoplasma gondii* highlights functional differences within the apicomplexan family. *Biochem J* 2002;368:923–9. [PubMed: 12238947]
37. Vercesi AE, Rodrigues CO, Uyemura SA, Zhong L, Moreno SNJ. Respiration and oxidative phosphorylation in the Apicomplexan parasite *Toxoplasma gondii*. *J Biol Chem* 1998;273:31040–7. [PubMed: 9813002]

38. Fleige T, Fischer K, Ferguson DJ, Gross U, Bohne W. Carbohydrate metabolism in the *Toxoplasma gondii* apicoplast: localization of three glycolytic isoenzymes, the single pyruvate dehydrogenase complex, and a plastid phosphate translocator. *Eukaryot Cell* 2007;6:984–96. [PubMed: 17449654]
39. Ohsaka A, Yoshikawa K, Hagiwara T. 1H-NMR spectroscopic study of aerobic glucose metabolism in *Toxoplasma gondii* harvested from the peritoneal exudate of experimentally infected mice. *Physiol Chem Phys* 1982;14:381–4. [PubMed: 7186134]
40. Fulton JD, Spooner DF. Metabolic studies on *Toxoplasma gondii*. *Exp Parasitol* 1960;9:293–301. [PubMed: 13825640]
41. Coppens I, Dunn JD, Romano JD, Pypaert M, Zhang H, Boothroyd JC, et al. *Toxoplasma gondii* sequesters lysosomes from mammalian hosts in the vacuolar space. *Cell* 2006;125:261–74. [PubMed: 16630815]
42. Halonen SK, Weidner E. Overcoating of *Toxoplasma* parasitophorous vacuoles with host cell vimentin type intermediate filaments. *J Eukaryot Microbiol* 1994;41:65–71. [PubMed: 8124268]
43. Crawford MJ, Thomsen-Zieger N, Ray M, Schachtner J, Roos DS, Seeber F. *Toxoplasma gondii* scavenges host-derived lipoic acid despite its de novo synthesis in the apicoplast. *EMBO J* 2006;25:3214–22. [PubMed: 16778769]
44. Sinai A, Webster P, Joiner K. Association of host cell endoplasmic reticulum and mitochondria with the *Toxoplasma gondii* parasitophorous vacuole membrane: a high affinity interaction. *J Cell Sci* 1997;110:2117–28. [PubMed: 9378762]
45. Sinai AP, Joiner KA. The *Toxoplasma gondii* protein ROP2 mediates host organelle association with the parasitophorous vacuole membrane. *J Cell Biol* 2001;154:95–108. [PubMed: 11448993]
46. El Hajj H, Lebrun M, Fourmaux MN, Vial H, Dubremetz JF. Inverted topology of the *Toxoplasma gondii* ROP5 rhoptyr protein provides new insights into the association of the ROP2 protein family with the parasitophorous vacuole membrane. *Cell Microbiol* 2007;9:54–64. [PubMed: 16879455]
47. Blader JJ, Manger ID, Boothroyd JC. Micro-array analysis reveals previously unknown changes in *Toxoplasma gondii*-infected human cells. *J Biol Chem* 2001;276:24223–31. [PubMed: 11294868]
48. Gail M, Gross U, Bohne W. Transcriptional profile of *Toxoplasma gondii*-infected human fibroblasts as revealed by gene-array hybridization. *Mol Genet Genom* 2001;265:905–12.
49. Zhao RY, Elder RT. Viral infections and cell cycle G2/M regulation. *Cell Res* 2005;15:143–9. [PubMed: 15780175]
50. Dobbelaere DA, Kuenzi P. The strategies of the Theileria parasite: a new twist in host-pathogen interactions. *Curr Opin Immunol* 2004;16:524–30. [PubMed: 15245750]
51. Brunet J, Pfaff AW, Abidi A, Unoki M, Nakamura Y, Guinard M, et al. *Toxoplasma gondii* exploits UHRF1 and induces host cell cycle arrest at G2 to enable its proliferation. *Cell Microbiol* 2008;10:908–20. [PubMed: 18005238]
52. Molestina RE, El-Guendy N, Sinai AP. Infection with *Toxoplasma gondii* results in dysregulation of the host cell cycle. *Cell Microbiol* 2008;10:1153–65. [PubMed: 18182087]
53. Lavine MD, Arrizabalaga G. Exit from host cells by the pathogenic parasite *Toxoplasma gondii* does not require motility. *Eukaryotic Cell* 2008;7:131–40. [PubMed: 17993573]
54. Dvorak JA, Crane MS. Vertebrate cell cycle modulates infection by protozoan parasites. *Science* 1981;214:1034–6. [PubMed: 7029713]
55. Grimwood J, Mineo JR, Kasper LH. Attachment of *Toxoplasma gondii* to host cells is host cell cycle dependent. *Infect Immun* 1996;64:4099–104. [PubMed: 8926075]
56. Youn JH, Nam HW, Kim DJ, Park YM, Kim WK, Kim WS, et al. Cell cycle-dependent entry of *Toxoplasma gondii* into synchronized HL-60 cells. *Kisaengchunghak Chapchi* 1991;29:121–8. [PubMed: 1954195]
57. Walker ME, Hjort EE, Smith SS, Tripathi A, Hornick JE, Hinchcliffe EH, et al. *Toxoplasma gondii* actively remodels the microtubule network in host cells. *Microbes Infect* 2008;10:1440–9. [PubMed: 18983931]
58. Chaussabel D, Semnani RT, McDowell MA, Sacks D, Sher A, Nutman TB. Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. *Blood* 2003;102:672–81. [PubMed: 12663451]
59. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. *Sci STKE* 2007;407:cm8. [PubMed: 17925579]

60. Zinkernagel AS, Johnson RS, Nizet V. Hypoxia inducible factor (HIF) function in innate immunity and infection. *J Mol Med* 2007;85:1339–46. [PubMed: 18030436]
61. Spear W, Chan D, Coppens I, Johnson RS, Giaccia A, Blader IJ. The host cell transcription factor hypoxia-inducible factor 1 is required for *Toxoplasma gondii* growth and survival at physiological oxygen levels. *Cell Microbiol* 2006;8:339–52. [PubMed: 16441443]
62. Phelps E, Sweeney K, Blader IJ. *Toxoplasma gondii* rhoptry discharge correlates with activation of the EGR2 host cell transcription factor. *Infect Immun* 2008;76:4703–12. [PubMed: 18678671]
63. Molestina RE, Sinai AP. Host and parasite-derived IKK activities direct distinct temporal phases of NF-kappaB activation and target gene expression following *Toxoplasma gondii* infection. *J Cell Sci* 2005;118:5785–96. [PubMed: 16339966]
64. Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R, Kufe DW. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. *Proc Natl Acad Sci USA* 1993;90:2419–22. [PubMed: 8384722]
65. Huang RP, Wu JX, Fan Y, Adamson ED. UV activates growth factor receptors via reactive oxygen intermediates. *J Cell Biol* 1996;133:211–20. [PubMed: 8601609]
66. Mechta-Grigoriou F, Gerald D, Yaniv M. The mammalian Jun proteins: redundancy and specificity. *Oncogene* 2001;20:2378–89. [PubMed: 11402334]
67. Molestina RE, Payne TM, Coppens I, Sinai AP. Activation of NF- $\kappa$ B by *Toxoplasma gondii* correlates with increased expression of antiapoptotic genes and localization of phosphorylated I  $\kappa$ B to the parasitophorous vacuole membrane. *J Cell Sci* 2003;116:4359–71. [PubMed: 12966164]
68. Kim JM, Oh YK, Kim YJ, Cho SJ, Ahn MH, Cho YJ. Nuclear factor-kappa B plays a major role in the regulation of chemokine expression of HeLa cells in response to *Toxoplasma gondii* infection. *Parasitol Res* 2001;87:758–63. [PubMed: 11570562]
69. Butcher BA, Kim L, Johnson PF, Denkers EY. *Toxoplasma gondii* tachyzoites inhibit proinflammatory cytokine induction in infected macrophages by preventing nuclear translocation of the transcription factor NF-kappa B. *J Immunol* 2001;167:2193–201. [PubMed: 11490005]
70. Shapira S, Harb OS, Margarit J, Matrajt M, Han J, Hoffmann A, et al. Initiation and termination of NF-kappaB signaling by the intracellular protozoan parasite *Toxoplasma gondii*. *J Cell Sci* 2005;118:3501–8. [PubMed: 16079291]
71. Caamano J, Alexander J, Craig L, Bravo R, Hunter CA. The NF-kappa B family member RelB is required for innate and adaptive immunity to *Toxoplasma gondii*. *J Immunol* 1999;163:4453–61. [PubMed: 10510387]
72. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A, et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. *J Exp Med* 1998;187:147–59. [PubMed: 9432973]
73. Caamano J, Tato C, Cai G, Villegas EN, Speirs K, Craig L, et al. Identification of a role for NF- $\kappa$ B2 in the regulation of apoptosis and in maintenance of T cell-mediated immunity to *Toxoplasma gondii*. *J Immunol* 2000;165:5720–8. [PubMed: 11067930]
74. Payne TM, Molestina RE, Sinai AP. Inhibition of caspase activation and a requirement for NF- $\kappa$ B function in the *Toxoplasma gondii*-mediated blockade of host apoptosis. *J Cell Sci* 2003;116:4345–58. [PubMed: 12966169]
75. Laliberte J, Carruthers VB. Host cell manipulation by the human pathogen *Toxoplasma gondii*. *Cell Mol Life Sci* 2008;65:1900–15. [PubMed: 18327664]
76. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. *Annu Rev Immunol* 1998;16:225–60. [PubMed: 9597130]
77. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. *Nat Rev Mol Cell Biol* 2007;8:49–62. [PubMed: 17183360]
78. Kim L, Butcher BA, Denkers EY. *Toxoplasma gondii* Interferes with Lipopolysaccharide-induced mitogen-activated protein kinase activation by mechanisms distinct from Endotoxin tolerance. *J Immunol* 2004;172:3003–10. [PubMed: 14978104]

79. Sinai AP, Payne TM, Carmen JC, Hardi L, Watson SJ, Molestina RE. Mechanisms underlying the manipulation of host apoptotic pathways by *Toxoplasma gondii*. *Int J Parasitol* 2004;34:381–91. [PubMed: 15003498]
80. Molestina RE, Sinai AP. Detection of a novel parasite kinase activity at the *Toxoplasma gondii* parasitophorous vacuole membrane capable of phosphorylating host IkappaBalpha. *Cell Microbiol* 2005;7:351–62. [PubMed: 15679838]
81. Dobbin CA, Smith NC, Johnson AM. Heat shock protein 70 is a potential virulence factor in murine toxoplasma infection via immunomodulation of host NF-kappa B and nitric oxide. *J Immunol* 2002;169:958–65. [PubMed: 12097402]
82. Robben PM, Mordue DG, Truscott SM, Takeda K, Akira S, Sibley LD. Production of IL-12 by macrophages infected with *Toxoplasma gondii* depends on the parasite genotype. *J Immunol* 2004;172:3686–94. [PubMed: 15004172]
83. Kim SK, Fouts AE, Boothroyd JC. *Toxoplasma gondii* dysregulates IFN-gamma-inducible gene expression in human fibroblasts: insights from a genome-wide transcriptional profiling. *J Immunol* 2007;178:5154–65. [PubMed: 17404298]
84. Weiss LM, Kim K. The development and biology of bradyzoites of *Toxoplasma gondii*. *Front Biosci* 2000;5:D391–405. [PubMed: 10762601]
85. Lyons RE, McLeod R, Roberts CW. *Toxoplasma gondii* tachyzoite-bradyzoite interconversion. *Trends Parasitol* 2002;18:198–201. [PubMed: 11983592]
86. Jones TC, Bienz KA, Erb P. In vitro cultivation of *Toxoplasma gondii* cysts in astrocytes in the presence of gamma interferon. *Infect Immun* 1986;51:147–56. [PubMed: 3079728]
87. Bohne W, Heesemann J, Gross U. Induction of bradyzoite-specific *Toxoplasma gondii* antigens in gamma interferon-treated mouse macrophages. *Infect Immun* 1993;61:1141–5. [PubMed: 8432596]
88. Soete M, Camus D, Dubremetz JF. Experimental induction of bradyzoite-specific antigen expression and cyst formation by the RH strain of *Toxoplasma gondii* in vitro. *Exp Parasitol* 1994;78:361–70. [PubMed: 8206135]
89. Radke JR, Donald RG, Eibs A, Jerome ME, Behnke MS, Liberator P, et al. Changes in the expression of human cell division autoantigen-1 influence *Toxoplasma gondii* growth and development. *PLoS Pathog* 2006;2:e105. [PubMed: 17069459]
90. Guimaraes EV, de Carvalho L, Barbosa HS. Primary culture of skeletal muscle cells as a model for studies of *Toxoplasma gondii* cystogenesis. *J Parasitol* 2008;94:72–83. [PubMed: 18372624]
91. Luder CG, Giraldo-Velasquez M, Sendtner M, Gross U. *Toxoplasma gondii* in primary rat CNS cells: differential contribution of neurons, astrocytes, and microglial cells for the intracerebral development and stage differentiation. *Exp Parasitol* 1999;93:23–32. [PubMed: 10464035]
92. Ferreira-da-Silva MD, Takacs AC, Barbosa HS, Gross U, Luder CG. Primary skeletal muscle cells trigger spontaneous *Toxoplasma gondii* tachyzoite-to-bradyzoite conversion at higher rates than fibroblasts. *Int J Med Microbiol*. 2008
93. Dzierszinski F, Nishi M, Ouko L, Roos DS. Dynamics of *Toxoplasma gondii* differentiation. *Eukaryot Cell* 2004;3:992–1003. [PubMed: 15302832]
94. Radke JR, Guerini MN, Jerome M, White MW. A change in the premitotic period of the cell cycle is associated with bradyzoite differentiation in *Toxoplasma gondii*. *Mol Biochem Parasitol* 2003;131:119–27. [PubMed: 14511810]
95. Mineo JR, McLeod R, Mack D, Smith J, Khan IA, Ely KH, et al. Antibodies to *Toxoplasma gondii* major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection. *J Immunol* 1993;150:3951–64. [PubMed: 7682587]
96. Khan IA, Smith KA, Kasper LH. Induction of antigen-specific parasiticidal cytotoxic T cell splenocytes by a major membrane protein (P30) of *Toxoplasma gondii*. *J Immunol* 1988;141:3600–5. [PubMed: 2460541]
97. Handman E, Goding JW, Remington JS. Detection and characterization of membrane antigens of *Toxoplasma gondii*. *J Immunol* 1980;124:2578–83. [PubMed: 7373040]
98. Sharma SD, Mullenax J, Araujo FG, Erlich HA, Remington JS. Western Blot analysis of the antigens of *Toxoplasma gondii* recognized by human IgM and IgG antibodies. *J Immunol* 1983;131:977–83. [PubMed: 6863940]


99. Parmley SF, Sgarlato GD, Mark J, Prince JB, Remington JS. Expression, characterization, and serologic reactivity of recombinant surface antigen P22 of *Toxoplasma gondii*. *J Clin Microbiol* 1992;30:1127–33. [PubMed: 1583109]
100. Sayles PC, Gibson GW, Johnson LL. B cells are essential for vaccination-induced resistance to virulent *Toxoplasma gondii*. *Infect Immun* 2000;68:1026–33. [PubMed: 10678903]
101. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. *Proc Natl Acad Sci USA* 1993;90:6115–9. see comments. [PubMed: 8100999]
102. Scharton-Kersten TM, Wynn TA, Denkers EY, Bala S, Grunvald E, Hieny S, et al. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to *Toxoplasma gondii* while failing to control acute infection. *J Immunol* 1996;157:4045–54. [PubMed: 8892638]
103. Mueller A, Strange PG. The chemokine receptor, CCR5. *Int J Biochem Cell Biol* 2004;36:35–8. [PubMed: 14592532]
104. Aliberti J, Sousa CRE, Schito M, Hieny S, Wells T, Huffnagel GB, et al. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha(1) dendritic cells. *Nat Immunol* 2000;1:83–7. [PubMed: 10881180]
105. Aliberti J, Valenzuela JG, Carruthers VB, Hieny S, Andersen J, Charest H, et al. Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. *Nat Immunol* 2003;4:485–90. [PubMed: 12665855]
106. Takeda K, Kaisho T, Akira S. Toll-like receptors. *Annu Rev Immunol* 2003;21:335–76. [PubMed: 12524386]
107. Yarovinsky F, Zhang D, Andersen JF, Bannenberg GL, Serhan CN, Hayden MS, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. *Science* 2005;308:1626–9. [PubMed: 15860593]
108. Mun HS, Aosai F, Norose K, Piao LX, Fang H, Akira S, et al. Toll-like receptor 4 mediates tolerance in macrophages stimulated with *Toxoplasma gondii*-derived heat shock protein 70. *Infect Immun* 2005;73:4634–42. [PubMed: 16040976]
109. Debierre-Grockiego F, Azzouz N, Schmidt J, Dubremetz JF, Geyer H, Geyer R, et al. Roles of glycosylphosphatidylinositols of *Toxoplasma gondii*. Induction of tumor necrosis factor-alpha production in macrophages. *J Biol Chem* 2003;278:32987–93. [PubMed: 12815041]
110. Debierre-Grockiego F, Campos MA, Azzouz N, Schmidt J, Bieker U, Resende MG, et al. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from *Toxoplasma gondii*. *J Immunol* 2007;179:1129–37. [PubMed: 17617606]
111. Mun HS, Aosai F, Norose K, Chen M, Piao LX, Takeuchi O, et al. TLR2 as an essential molecule for protective immunity against *Toxoplasma gondii* infection. *Int Immunol* 2003;15:1081–7. [PubMed: 12917260]
112. Scanga CA, Aliberti J, Jankovic D, Tilloy F, Bennouna S, Denkers EY, et al. Cutting edge: MyD88 is required for resistance to *Toxoplasma gondii* infection and regulates parasite-induced IL-12 production by dendritic cells. *J Immunol* 2002;168:5997–6001. [PubMed: 12055206]
113. Minns LA, Menard LC, Foureau DM, Darche S, Ronet C, Mielcarz DW, et al. TLR9 is required for the gut-associated lymphoid tissue response following oral infection of *Toxoplasma gondii*. *J Immunol* 2006;176:7589–97. [PubMed: 16751405]
114. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. *Immunity* 1998;9:143–50. [PubMed: 9697844]
115. Cai G, Kastelein R, Hunter CA. Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to *Toxoplasma gondii*. *Infect Immun* 2000;68:6932–8. [PubMed: 11083816]
116. Mordue DG, Monroy F, La Regina M, Dinarello CA, Sibley LD. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. *J Immunol* 2001;167:4574–84. [PubMed: 11591786]
117. Chang HR, Grau GE, Pechere JC. Role of TNF and IL-1 in infections with *Toxoplasma gondii*. *Immunology* 1990;69:33–7. [PubMed: 2107144]
118. Hunter CA, Chizzonite R, Remington JS. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. *J Immunol* 1995;155:4347–54. [PubMed: 7594594]



119. Plattner F, Yarovinsky F, Romero S, Didry D, Carlier MF, Sher A, et al. Toxoplasma profilin is essential for host cell invasion and TLR11-dependent induction of an interleukin-12 response. *Cell Host Microbe* 2008;3:77–87. [PubMed: 18312842]
120. Yarovinsky F, Kanzler H, Hieny S, Coffman RL, Sher A. Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+T cell response. *Immunity* 2006;25:655–64. [PubMed: 17000122]
121. Zhang DK, Zhang GL, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. *Science* 2004;303:1522–6. [PubMed: 15001781]
122. LaRosa DF, Stumhofer JS, Gelman AE, Rahman AH, Taylor DK, Hunter CA, et al. T cell expression of MyD88 is required for resistance to *Toxoplasma gondii*. *Proc Natl Acad Sci USA* 2008;105:3855–60. [PubMed: 18308927]
123. Jankovic D, Kullberg MC, Hieny S, Caspar P, Collazo CM, Sher A. In the absence of IL-12, CD4 (+) T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10(–/–) setting. *Immunity* 2002;16:429–39. [PubMed: 11911827]
124. Sukhumavasi W, Egan CE, Warren AL, Taylor GA, Fox BA, Bzik DJ, et al. TLR adaptor MyD88 is essential for pathogen control during oral *toxoplasma gondii* infection but not adaptive immunity induced by a vaccine strain of the parasite. *J Immunol* 2008;181:3464–73. [PubMed: 18714019]
125. Yap GS, Sher A. Effector cells of both non-hemopoietic and hemopoietic origin are required for interferon (IFN)-gamma- and tumor necrosis factor (TNF)-alpha-dependent host resistance to the intracellular pathogen, *Toxoplasma gondii*. *J Exp Med* 1999;189:1083–92. [PubMed: 10190899]
126. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against *Toxoplasma gondii*. *Science* 1988;240:516–8. [PubMed: 3128869]
127. Suzuki Y, Conley FK, Remington JS. Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. *J Immunol* 1989;143:2045–50. [PubMed: 2506275]
128. Collazo CM, Yap GS, Sempowski GD, Lusby KC, Tessarollo L, Woude GF, et al. Inactivation of LRG-47 and IRG-47 reveals a family of interferon gamma-inducible genes with essential, pathogen-specific roles in resistance to infection. *J Exp Med* 2001;194:181–8. [PubMed: 11457893]
129. Scharton-Kersten TM, Yap G, Magram J, Sher A. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen *Toxoplasma gondii*. *J Exp Med* 1997;185:1261–73. [PubMed: 9104813]
130. Ling YM, Shaw MH, Ayala C, Coppens I, Taylor GA, Ferguson DJ, et al. Vacuolar and plasma membrane stripping and autophagic elimination of *Toxoplasma gondii* in primed effector macrophages. *J Exp Med* 2006;203:2063–71. [PubMed: 16940170]
131. MacMicking JD. IFN-inducible GTPases and immunity to intracellular pathogens. *Trends Immunol* 2004;25:601–9. [PubMed: 15489189]
132. Denis M. Human monocytes/macrophages: NO or no NO? *J Leukoc Biol* 1994;55:682–4. [PubMed: 8182347]
133. Murray HW, Teitelbaum R, Hariprasad J. Response to treatment for an intracellular infection in a T cell-deficient host: toxoplasmosis in nude mice. *J Infect Dis* 1993;167:1173–7. [PubMed: 8486951]
134. Schwartzman JD, Gonias SL, Pfefferkorn ER. Murine gamma interferon fails to inhibit *Toxoplasma gondii* growth in murine fibroblasts. *Infect Immun* 1990;58:833–4. [PubMed: 2106497]
135. Halonen SK, Weiss LM. Investigation into the mechanism of gamma interferon-mediated inhibition of *Toxoplasma gondii* in murine astrocytes. *Infect Immun* 2000;68:3426–30. [PubMed: 10816494]
136. Halonen SK, Chiu F, Weiss LM. Effect of cytokines on growth of *Toxoplasma gondii* in murine astrocytes. *Infect Immun* 1998;66:4989–93. [PubMed: 9746608]
137. Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. *Trends Immunol* 2002;23:96–101. [PubMed: 11929133]
138. Luder CG, Walter W, Beuerle B, Maeurer MJ, Gross U. *Toxoplasma gondii* down-regulates MHC class II gene expression and antigen presentation by murine macrophages via interference with nuclear translocation of STAT1-alpha. *Eur J Immunol* 2001;31:1475–84. [PubMed: 11465104]
139. Zimmermann S, Murray PJ, Heeg K, Dalpke AH. Induction of suppressor of cytokine signaling-1 by *Toxoplasma gondii* contributes to immune evasion in macrophages by blocking IFN-gamma signaling. *J Immunol* 2006;176:1840–7. [PubMed: 16424215]

140. Murray PJ. The JAK-STAT signaling pathway: input and output integration. *J Immunol* 2007;178:2623–9. [PubMed: 17312100]
141. Lang C, Algner M, Beinert N, Gross U, Luder CG. Diverse mechanisms employed by *Toxoplasma gondii* to inhibit IFN-gamma-induced major histocompatibility complex class II gene expression. *Microbes Infect* 2006;8:1994–2005. [PubMed: 16824778]
142. Sumyuen MH, Garin YJ, Derouin F. Early kinetics of *Toxoplasma gondii* infection in mice infected orally with cysts of an avirulent strain. *J Parasitol* 1995;81:327–9. [PubMed: 7707221]
143. Chtanova T, Schaeffer M, Han SJ, van Dooren GG, Nollmann M, Herzmark P, et al. Dynamics of neutrophil migration in lymph nodes during infection. *Immunity* 2008;29:487–96. [PubMed: 18718768]
144. Channon JY, Seguin RM, Kasper LH. Differential infectivity and division of *Toxoplasma gondii* in human peripheral blood leukocytes. *Infect Immun* 2000;68:4822–6. [PubMed: 10899898]
145. Diana J, Vincent C, Peyron F, Picot S, Schmitt D, Persat F. *Toxoplasma gondii* regulates recruitment and migration of human dendritic cells via different soluble secreted factors. *Clin Exp Immunol* 2005;141:475–84. [PubMed: 16045737]
146. Diana J, Persat F, Staquet MJ, Assossou O, Ferrandiz J, Gariazzo MJ, et al. Migration and maturation of human dendritic cells infected with *Toxoplasma gondii* depend on parasite strain type. *FEMS Immunol Med Microbiol* 2004;42:321–31. [PubMed: 15477046]
147. Lambert H, Hitziger N, Dellacasa I, Svensson M, Barragan A. Induction of dendritic cell migration upon *Toxoplasma gondii* infection potentiates parasite dissemination. *Cell Microbiol* 2006;8:1611–23. [PubMed: 16984416]
148. Bierly AL, Shufesky WJ, Sukhumavasi W, Morelli AE, Denkers EY. Dendritic cells expressing plasmacytoid marker PDCA-1 are Trojan horses during *Toxoplasma gondii* infection. *J Immunol* 2008;181:8485–91. [PubMed: 19050266]
149. Liu CH, Fan YT, Dias A, Esper L, Corn RA, Bafica A, et al. Cutting edge: dendritic cells are essential for in vivo IL-12 production and development of resistance against *Toxoplasma gondii* infection in mice. *J Immunol* 2006;177:31–5. [PubMed: 16785494]
150. Sapozhnikov A, Fischer JA, Zaft T, Krauthgamer R, Dzionek A, Jung S. Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. *J Exp Med* 2007;204:1923–33. [PubMed: 17646404]
151. Pepper M, Dzierszynski F, Wilson E, Tait E, Fang Q, Yarovinsky F, et al. Plasmacytoid dendritic cells are activated by *Toxoplasma gondii* to present antigen and produce cytokines. *J Immunol* 2008;180:6229–36. [PubMed: 18424745]
152. Ajzenberg D, Banuls AL, Su C, Dumetre A, Demar M, Carne B, et al. Genetic diversity, clonality and sexuality in *Toxoplasma gondii*. *Int J Parasitol* 2004;34:1185–96. [PubMed: 15380690]
153. Howe DK, Sibley LD. *Toxoplasma gondii* comprises three clonal lineages: correlation of parasite genotype with human disease. *J Infect Dis* 1995;172:1561–6. [PubMed: 7594717]
154. Sibley LD, Boothroyd JC. Virulent strains of *Toxoplasma gondii* comprise a single clonal lineage. *Nature* 1992;359:82–5. [PubMed: 1355855]
155. Saeij JP, Coller S, Boyle JP, Jerome ME, White MW, Boothroyd JC. *Toxoplasma* co-opts host gene expression by injection of a polymorphic kinase homologue. *Nature* 2007;445:324–7. [PubMed: 17183270]
156. Boothroyd JC, Grigg ME. Population biology of *Toxoplasma gondii* and its relevance to human infectio: do different strains cause different disease? *Curr Opin Microbiol* 2002;5:438–42. [PubMed: 12160866]
157. Sibley LD, LeBlanc AJ, Pfefferkorn ER, Boothroyd JC. Generation of a restriction fragment length polymorphism linkage map for *Toxoplasma gondii*. *Genetics* 1992;132:1003–15. [PubMed: 1360931]
158. Ihle JN. The Stat family in cytokine signaling. *Curr Opin Cell Biol* 2001;13:211–7. [PubMed: 11248555]
159. Gavrilescu LC, Denkers EY. IFN-gamma overproduction and high level apoptosis are associated with high but not low virulence *Toxoplasma gondii* infection. *J Immunol* 2001;167:902–9. [PubMed: 11441097]

160. Nguyen TD, Bigaignon G, Markine-Goriaynoff D, Heremans H, Nguyen TN, Warnier G, et al. Virulent *Toxoplasma gondii* strain RH promotes T-cell-independent overproduction of proinflammatory cytokines IL12 and gamma-interferon. *J Med Microbiol* 2003;52(Pt10):869–76. [PubMed: 12972580]
161. Barragan A, Sibley LD. Transepithelial migration of *Toxoplasma gondii* is linked to parasite motility and virulence. *J Exp Med* 2002;195:1625–33. [PubMed: 12070289]
162. Saeij JP, Boyle JP, Grigg ME, Arrizabalaga G, Boothroyd JC. Bioluminescence imaging of *Toxoplasma gondii* infection in living mice reveals dramatic differences between strains. *Infect Immun* 2005;73:695–702. [PubMed: 15664907]
163. Taylor S, Barragan A, Su C, Fux B, Fentress SJ, Tang K, et al. A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen *Toxoplasma gondii*. *Science* 2006;314:1776–80. [PubMed: 17170305]
164. El Hajj H, Lebrun M, Arold ST, Vial H, Labesse G, Dubremetz JF. ROP18 is a Rhoptyr Kinase controlling the intracellular proliferation of *Toxoplasma gondii*. *PLoS Pathog* 2007;3:e14. [PubMed: 17305424]
165. Grigg ME, Bonnefoy S, Hehl AB, Suzuki Y, Boothroyd JC. Success and virulence in *Toxoplasma* as the result of sexual recombination between two distinct ancestries. *Science* 2001;294:161–5. [PubMed: 11588262]
166. Saeij JP, Boyle JP, Collier S, Taylor S, Sibley LD, Brooke-Powell ET, et al. Polymorphic secreted kinases are key virulence factors in toxoplasmosis. *Science* 2006;314:1780–3. [PubMed: 17170306]
167. Sullivan WJ Jr, Chiang CW, Wilson CM, Naguib FN, el Kouni MH, Donald RG, et al. Insertional tagging of at least two loci associated with resistance to adenine arabinoside in *Toxoplasma gondii*, and cloning of the adenosine kinase locus. *Mol Biochem Parasitol* 1999;103:1–14. [PubMed: 10514076]
168. Chaudhary K, Darling JA, Fohl LM, Sullivan WJ Jr, Donald RG, Pfefferkorn ER, et al. Purine salvage pathways in the apicomplexan parasite *Toxoplasma gondii*. *J Biol Chem* 2004;279:31221–7. [PubMed: 15140885]
169. Nicolle C, Manceaux L. Sur une infection a corps de Leishman (ou organismes voisins) du gondi. *C R Seances Acad Sci* 1908;147:763–6.
170. Nicolle C, Manceaux L. Sur une protozoaire nouveau du gondi. *C R Seances Acad Sci* 1909;148:369–72.
171. Carey KL, Westwood NJ, Mitchison TJ, Ward GE. A small-molecule approach to studying invasive mechanisms of *Toxoplasma gondii*. *Proc Natl Acad Sci USA* 2004;101:7433–8. [PubMed: 15123807]
172. Gubbels MJ, Lehmann M, Muthalagi M, Jerome ME, Brooks CF, Szatanek T, et al. Forward genetic analysis of the apicomplexan cell division cycle in *Toxoplasma gondii*. *PLoS Pathog* 2008;4:e36. [PubMed: 18282098]
173. Vyas A, Kim SK, Giacomini N, Boothroyd JC, Sapolsky RM. Behavioral changes induced by *Toxoplasma* infection of rodents are highly specific to aversion of cat odors. *Proc Natl Acad Sci USA* 2007;104:6442–7. [PubMed: 17404235]
174. Mortensen PB, Yolken RH, Lindum B, Sorensen T, Hougaard D, Pedersen BN. Toxoplasmosis and other early infections in relation to schizophrenia risk. *Schizophrenia Bull* 2005;31:232–3.
175. Berdoy M, Webster JP, Macdonald DW. Fatal attraction in rats infected with *Toxoplasma gondii*. *Proc Biol Sci* 2000;267:1591–4. [PubMed: 11007336]
176. Flegr J, Zitkova S, Kodym P, Frynta D. Induction of changes in human behaviour by the parasitic protozoan *Toxoplasma gondii*. *Parasitology* 1996;113:49–54. [PubMed: 8710414]
177. Gilbert LA, Ravindran S, Turetzky JM, Boothroyd JC, Bradley PJ. *Toxoplasma gondii* targets a protein phosphatase 2C to the nuclei of infected host cells. *Eukaryot Cell* 2007;6:73–83. [PubMed: 17085638]



**Fig. 1.**

Overview of *Toxoplasma* host cell interactions. (A). Innate immune responses are initiated by Toll-like receptor (TLR) and CCR5 recognition of *Toxoplasma*-derived factors. (B). Parasite invasion is accomplished by the release of micronemal adhesins that interact with host surface factors. This is then followed by rhoptry secretion that results in the formation of the moving junction and in the release of parasite factors (e.g ROP2 family members, ROP16, ROP18, and PP2c-hn) that either interact with the parasitophorous vacuole (PV) (ROP2 family and ROP18) or are transported to the host cytoplasm (ROP16) or nucleus [PP2c-hn (177)]. Some of these factors (ROP16 and ROP18) are polymorphic virulence factors. (C). Intracellular parasites reorganize host mitochondria and endoplasmic reticulum as well as the host microtubule organizing center and cytoskeleton around the PV. Host microtubules associated with LDL-loaded cholesterol form membrane tubules that push into the PV and are wrapped with the dense granule protein GRA7. (D). Small soluble nutrients freely diffuse across the PV and then are taken up by the parasite presumably by membrane transporters. (E). Host transcription is regulated either by the parasite directly activating host transcription factors or by the parasite triggering host signaling cascades that culminate in activating the host transcription factors. Changes in host gene expression can act to either promote parasite growth, immune evasion, virulence, or bradyzoite development.